News Novo rises on Wegovy sales leap, but warns of a slowdown Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.
News Two more biotechs, Metsera and Maze, cross IPO finish line Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.
News Veru shares plunge despite positive data in obesity trial Veru's obesity candidate achieved the objective of preserving muscle in people taking weight-loss drug Wegovy, but its share price still fell sharply.
Patients Social media advocacy: Healthcare professionals and the Trea... Social media is a hub of opinion, argument, and advocacy that traverses a virtually endless spectrum.
News Novo Nordisk leaps on new obesity drug data Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.
News Large study points to benefits - and risks - of GLP-1 drugs The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.
Patients New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx an... At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
